Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab, Apatinib and Nab-paclitaxel in Advanced Gastric Cancer
NCT04182724Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2019
- Primary completion
- May 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT04182724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04182724.